Bridging to survivorship in breast cancer: Learning how treatment impacts mental health among early-stage breast cancer survivors.

Authors

Debra Patt

Debra A. Patt

Texas Oncology/The US Oncology Network, Austin, TX

Debra A. Patt, Janet L. Espirito, Robyn K. Harrell, Brian Turnwald, Debajyoti Bhowmik, Barry Don Brooks, Neelima Denduluri, J. Russell Hoverman

Organizations

Texas Oncology/The US Oncology Network, Austin, TX, The US Oncology Network/McKesson Specialty Health, The Woodlands, TX, Texas Oncology/The US Oncology Network, Dallas, TX, Virginia Cancer Specialists/US Oncology, Arlington, VA

Research Funding

No funding sources reported

Background: Depression (D) and anxiety (A) complicate survivorship in breast cancer (BC) patients (pts). The prevalence of D and A after BC treatment (Tx) in the community and concordance with BC Tx type is poorly described, but vitally important to characterize risks of Tx and optimize support for BC pts and goals for survivorship care planning. Methods: We queried the electronic health record (EHR), iKnowMed, from a a large network of community oncology practices for pts treated with stage I-III breast cancer from 2007-2010 with at least 5 visits and follow up through 2012 for our retrospective study. We excluded pts who developed metastatic disease or died. We stratified pts by chemotherapy (CT) utilization (yes/no),hormone receptor (HR) status, age, and documented body mass index (BMI) at diagnosis, and post diagnosis development of D (y/n), A (y/n) or utilization of venlafaxine (E) like antidepressants (Ads), non-E like Ads or anti-A medications within the study period. Time to onset of A or D was analyzed using Cox proportional hazard methodology. Results: We identified 8,506 patients with a documented BMI at 1, 2, and 3 years (yrs) post diagnosis. 4,369 (51%) of patients received adjuvant CT and 4,137 (49%) did not. Baseline characteristics were similar between tx groups, and active D or A was low at the time of dx, but as a whole rose to 41% during the study period. Pts with pre-existing D or A at the time of diagnosis were excluded. CT increases the risk of D or A (HR: 1.23, CI: 1.15-1.33). HR+ status also increases the risk of D or A (HR: 1.21, CI:1.11-1.32). Age conveyed a small diminished risk of D or A (HR: 0.98, CI: 0.98-0.99) while baseline BMI conveyed a small increased risk (HR: 1.02, CI 1.01-1.3). When excluding E like compounds that are often used to treat hot flashes in BC pts, CT was still found to have an increased risk of D or A (HR: 1.28, CI: 1.18-1.39), and HR+ was still associated with higher risk of D or A as well (HR: 1.11, CI: 1.01-1.22). Conclusions: Mental health disorders such as D and A are common among BC survivors, and more prevalent among BC survivors who received CT and have HR+ disease. This warrants further investigation on how to evaluate and support the mental health needs of BC survivors.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2013 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Science of Quality

Track

Science of Quality,Health Reform: Implications for Costs and Quality ,Practice of Quality

Sub Track

HIT Analytics

Citation

J Clin Oncol 31, 2013 (suppl 31; abstr 33)

Abstract #

33

Poster Bd #

B9

Abstract Disclosures

Similar Abstracts

First Author: Jingran Ji

First Author: Nayha Tahir

Abstract

2023 ASCO Quality Care Symposium

Demand for oncology visits among low-risk breast cancer survivors.

First Author: Emily H. Douglas